Clinical Study for AL-CM
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04924998
Collaborator
(none)
400
1
120
3.3
Study Details
Study Description
Brief Summary
In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Clinical Study Protocol for the Treatment of Immunoglobulin Light Chain Amyloidosis Cardiomyopathy
Anticipated Study Start Date
:
Jun 6, 2021
Anticipated Primary Completion Date
:
Jun 6, 2031
Anticipated Study Completion Date
:
Jun 6, 2031
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| AL-CM
|
Drug: current treatment of AL-CM
current treatment of AL-CM
|
Outcome Measures
Primary Outcome Measures
- Primary Outcome [10 year]
Cardiovascular death, myocardial infarction, and stroke
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
-
Patients have the ability to understand the test, can cooperate with investigators.
Exclusion Criteria:
- Unable to understand or unwilling to fill in informed consent forms or follow visitors
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China | Hangzhou | Zhejiang | China |
Sponsors and Collaborators
- Second Affiliated Hospital, School of Medicine, Zhejiang University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT04924998
Other Study ID Numbers:
- 2021-0133
First Posted:
Jun 14, 2021
Last Update Posted:
Jun 14, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: